Most Read Articles
Stephen Padilla, 09 Nov 2020
Tocilizumab (TCZ) therapy appears to be effective in patients at risk of cytokine release syndrome (CRS) from the novel coronavirus disease (COVID-19), suggests a study presented at ID Week 2020. Those receiving TCZ in a nonintensive care unit (non-ICU) setting show better response than ICU patients.
Stephen Padilla, 10 Nov 2020
Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.

Mirabegron safe to use as add-on in tamsulosin-treated male patients with LUTS

16 Nov 2020

Mirabegron appears to be a safe add-on therapy in men receiving tamsulosin for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia, according to data from the phase IV PLUS study.

PLUS comprised a 4-week run-in period (tamsulosin 0.4 mg) and a 12-week blinded treatment period where patients were randomized to receive add-on treatment with mirabegron 25 mg (n=352) or placebo (n=354). Doses in the blinded treatment period were doubled after 4 weeks.

Patient demographics were similar between the two groups. The mean age of the entire population was 65 years, and mean body mass index was 29 kg/m2. Most patients in both groups had hypertension (55.7 percent in the mirabegron group vs 60.2 percent in the placebo group). Other comorbidities included hypercholesterolaemia (26.4 percent vs 26.8 percent) and gastroesophageal reflux disease (13.4 percent vs 11.3 percent).

The safety data revealed that drug-related adverse events (AEs) occurred with greater frequency in the mirabegron group, whereas the frequency of overall AEs was higher in the placebo group. Hypertension, headache, and nasopharyngitis were the most common AEs, and most of them were mild or moderate in severity.

Drug-related serious AEs occurred in two patients on mirabegron (acute myocardial infarction with cerebral infarction, angina pectoris) and one on placebo (lacunar stroke). Special interest AEs were rare, the most common of which was urinary retention, with two mirabegron-treated patients requiring catheterization; neither led to discontinuation.

Blood pressure and pulse rate remained relatively stable, and similar electrocardiogram parameters were similar in both groups. Changes in mean postvoid residual volume and Qmax were not clinically meaningful.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 09 Nov 2020
Tocilizumab (TCZ) therapy appears to be effective in patients at risk of cytokine release syndrome (CRS) from the novel coronavirus disease (COVID-19), suggests a study presented at ID Week 2020. Those receiving TCZ in a nonintensive care unit (non-ICU) setting show better response than ICU patients.
Stephen Padilla, 10 Nov 2020
Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.